Combination chemotherapy and ALVAC-CEA/B7. 1 vaccine in patients with metastatic colorectal cancer
…, M DeBenedette, D Salha, T Vogel, I Elias… - Clinical Cancer …, 2008 - AACR
Purpose: The combination of vaccines and chemotherapy holds promise for cancer therapy,
but the effect of cytotoxic chemotherapy on vaccine-induced antitumor immunity is unknown. …
but the effect of cytotoxic chemotherapy on vaccine-induced antitumor immunity is unknown. …
Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
…, J Wheler, S Moulder, T Helgason, S Li, I Elias… - Clinical Cancer …, 2013 - AACR
Purpose: This dose-finding phase I study investigated the maximum-tolerated dose (MTD)
and safety of weekly nanoparticle albumin-bound rapamycin (nab-rapamycin) in patients with …
and safety of weekly nanoparticle albumin-bound rapamycin (nab-rapamycin) in patients with …
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
…, S Kesari, R Magge, B Winograd, I Elias… - Neuro-Oncology …, 2021 - academic.oup.com
Background This phase I/II trial in patients with recurrent glioblastoma (GBM) evaluates the
safety and preliminary efficacy of marizomib, an irreversible pan-proteasome inhibitor that …
safety and preliminary efficacy of marizomib, an irreversible pan-proteasome inhibitor that …
[HTML][HTML] Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: a collaboration with innovative …
…, I Aerts, C Bergeron, P Hingorani, I Elias… - European journal of …, 2018 - Elsevier
Background nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and
preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in …
preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in …
Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-α2b: implications for cancer vaccines
…, R Uger, G Lumber, N Berinstein, I Elias… - Clinical cancer …, 2003 - AACR
Purpose: The therapeutic effectiveness of cancer vaccines, composed of tumor antigens
that are also self-antigens, may be limited by the normal mechanisms that preserve …
that are also self-antigens, may be limited by the normal mechanisms that preserve …
Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100
DE Spaner, I Astsaturov, T Vogel, T Petrella, I Elias… - Cancer, 2006 - Wiley Online Library
BACKGROUND The route of administration and extent of helper T‐cell activation are factors
that are likely to be important for the development of effective cancer vaccines. In order to …
that are likely to be important for the development of effective cancer vaccines. In order to …
Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor.
RL Leff, I Elias, M Ionescu, A Reiner… - The Journal of …, 2003 - jrheum.org
OBJECTIVE: To determine the effect of BAY 12-9566, a matrix metalloproteinase inhibitor,
on articular cartilage metabolism in patients with osteoarthritis (OA). METHODS: Thirty-five …
on articular cartilage metabolism in patients with osteoarthritis (OA). METHODS: Thirty-five …
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly …
…, A Desjardins, SD Reich, ML Casadebaig, I Elias… - 2019 - ascopubs.org
2021 Background: Proteasome inhibition sensitizes glioma cells to TMZ and RT, providing a
novel therapeutic strategy for GBM. MRZ, an irreversible, brain-penetrant, pan-proteasome …
novel therapeutic strategy for GBM. MRZ, an irreversible, brain-penetrant, pan-proteasome …
A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status.
…, R Kefford, C Loquai, A Testori, C Robert, M Li, I Elias… - 2013 - ascopubs.org
9030 Background: Activating mutations of BRAF V600 can be found in 40%-50% of
melanomas and are related to poor prognosis. In a phase 3 trial for the treatment of metastatic …
melanomas and are related to poor prognosis. In a phase 3 trial for the treatment of metastatic …
Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK).
…, I Aerts, C Bergeron, P Hingorani, I Elias… - 2016 - ascopubs.org
10551 Background: Although solvent-based paclitaxel has demonstrated activity in adult pts
with STs, solvents produce significant neurotoxicity in pediatric pts. nab-P is an albumin–…
with STs, solvents produce significant neurotoxicity in pediatric pts. nab-P is an albumin–…